HOME >> BIOLOGY >> NEWS
Braunschweig Prize 2003 for Molecular Cancer Therapy

Ten years ago the medic began working with the compound Imatinib that works against chronic myeloid leukemia (CML) and is commercially known as Glivec. Glivec blocks a protein that triggers the uncontrolled reproduction of white blood cells. "The name Brian Druker has become synonymous with a breakthrough in cancer therapy," said Braunschweig's mayor and chairman of the jury, Dr. Gert Hoffmann on the 8th of July after the vote of the council. Every year approximately 1700 people in Germany fall ill with CML. Some of the first patients to be treated with Glivec came from Germany.

Druker received his M.D. in 1981 from the University of California in San Diego. At Harvard Medical School he specialized in cancer research. Since 1993, Druker leads leukemia research at the Oregon Health & Science University Cancer Institute in Portland (USA). He is Investigator of the Howard Hughes Medical Institute and JELDWEN Chair of Leukemia Research. On the 27th of October he will accept the Braunschweig prize at the congress "Life in Tomorrow's World."

The American cancer researcher Prof. Dr. Brian Druker will be recognised for his research into molecular cancer ther-apy with the 50,000 Euro Braunschweig Prize, the highest research prize from a German city.

The 48-year-old medic is regarded as the pathfinder of the first tailor-made pill for the treatment of cancer. Ten years ago, in collaboration with the pharmaceutical company No-vartis, he identified the compound Imatinib, which in the meantime has become commercially available as Glivec. In contrast to chemotherapy that attacks both healthy and diseased cells, Imatinib targets a single protein that trig-gers the uncontrolled growth of white blood cells in chronic myeloid leukemia (CML). Every year approximately 1700 people in Germany fall ill with this blood cancer.

A recent study involving 1006 patients, comparing Glivec to standard therapy for CML, led by Druker, had to be stopped early because
'"/>

Contact: Jrgen Sperber
juergen.sperber@braunschweig.de
49-531-470-2212
Stadtverwaltung Braunschweig
8-Jul-2003


Page: 1 2

Related biology news :

1. Half-million dollar landmark achieved for the Methuselah Mouse Prize
2. Winner of 2004 EMBO Science Writing Prize announced
3. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
4. Stuart Lipton honored with Jung Prize for Medicine
5. 2004 Max Planck Research Prize for Martin Vingron and Eugene W. Myers
6. Scripps research scientist wins 2004 Koch Prize
7. Ohio State wetlands professor wins prestigious Water Prize
8. Tony Hunter and Raymond N. DuBois awarded Landon-AACR Prizes for Cancer Research
9. Leibniz Prizewinners 2004
10. Roderick MacKinnon wins 2003 Nobel Prize in Chemistry
11. Illinois professor wins Nobel Prize

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Braunschweig Prize for Molecular Cancer Therapy

(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market releases photos and video ... Square on Monday October 13 th . ... Tunnel and angel investor Mr. Chad A. Verdi ... of NXT-ID thanked his investors and employees "for their work and ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
Cached News: